Membrane-bound receptor activator of NFκB ligand (RANKL) activity displayed by osteoblasts is differentially regulated by osteolytic factors

Biochemical and Biophysical Research Communications

Volumn 422, Issue 1, 2012, Pages 48-53

  Singh, Preetinder P ^a   van der Kraan, A Gabrielle J ^a,b   Xu, Jiake ^c   Gillespie, Matthew T ^a,b   Quinn, Julian M W ^a,b  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Bone biology; Osteoblasts; Osteoclasts; RANKL; TGF

Indexed keywords

COLECALCIFEROL; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; PROSTAGLANDIN E2; RECOMBINANT RECEPTOR; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; BINDING KINETICS; CELL CULTURE; CELL LINE; CELL STIMULATION; CONTROLLED STUDY; KUSA O CELL; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; BIOLOGICAL ASSAY; CALCITRIOL; CELL LINE; CELL MEMBRANE; COCULTURE TECHNIQUES; DINOPROSTONE; GENES, REPORTER; LUCIFERASES; MICE; MICE, INBRED C57BL; NF-KAPPA B; OSTEOBLASTS; OSTEOLYSIS; OSTEOPROTEGERIN; PROMOTER REGIONS, GENETIC; RANK LIGAND; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 84861461064     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.04.103     Document Type: Article

References (23)

1. Yasuda H., Shima N., Nakagawa N., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 1998, 95:3597-3602.
2. Li J., Sarosi I., Yan X.Q., et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 2000, 97:1566-1571.
3. Anderson D.M., Maraskovsky E., Billingsley W.L., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390:175-179.
4. Rachner T.D., Khosla S., Hofbauer L.C. Osteoporosis: now and the future. Lancet 2011, 377:1276-1287.
5. Castellano D., Sepulveda J.M., Garcia-Escobar I., et al. The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist 2011, 16:136-145.
6. Horwood N.J., Elliott J., Martin T.J., et al. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998, 139:4743-4746.
7. Horwood N.J., Kartsogiannis V., Quinn J.M., et al. Activated T lymphocytes support osteoclast formation in vitro. Biochem. Biophys. Res. Commun. 1999, 265:144-150.
8. Farrugia A.N., Atkins G.J., To L.B., et al. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res. 2003, 63:5438-5445.
9. J. Xiong, C.A. O'Brien, Osteocyte RANKL: new insights into the control of bone remodeling, J. Bone Miner. Res. 27 (2012) 499-505.
10. Kartsogiannis V., Zhou H., Horwood N.J., et al. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 1999, 25:525-534.
11. Aoki S., Honma M., Kariya Y., et al. Function of OPG as a traffic regulator for RANKL is crucial for controlled osteoclastogenesis. J. Bone Miner. Res. 2010, 25:1907-1921.
12. Fazzalari N.L., Kuliwaba J.S., Atkins G.J., et al. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. J. Bone Miner. Res. 2001, 16:1015-1027.
13. Wong B.R., Josien R., Lee S.Y., et al. The TRAF family of signal transducers mediates NF-κB activation by the TRANCE receptor. J. Biol. Chem. 1998, 273:28355-28359.
14. Takayanagi H. The role of NFAT in osteoclast formation. Ann. NY Acad. Sci. 2007, 1116:227-237.
15. Allan E.H., Ho P.W., Umezawa A., et al. Differentiation potential of a mouse bone marrow stromal cell line. J. Cell. Biochem. 2003, 90:158-169.
16. Tikellis C., Xuereb L., Casley D., et al. Calcitonin receptor isoforms expressed in the developing rat kidney. Kidney Int. 2003, 63:416-426.
17. Wang C., Steer J.H., Joyce D.A., et al. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation. J. Bone Miner. Res. 2003, 18:2159-2168.
18. Quinn J.M., Whitty G.A., Byrne R.J., et al. The generation of highly enriched osteoclast-lineage cell populations. Bone 2002, 30:164-170.
19. Quinn J.M., Morfis M., Lam M.H., et al. Calcitonin receptor antibodies in the identification of osteoclasts. Bone 1999, 25:1-8.
20. Quinn J.M., Itoh K., Udagawa N., et al. Transforming growth factor beta affects osteoclast differentiation via direct and indirect action. J. Bone Miner. Res. 2001, 16:1787-1794.
21. Quinn J.M., Horwood N.J., Elliott J., et al. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. J. Bone Miner. Res. 2000, 15:1459-1466.
22. Lum L., Wong B.R., Josien R., et al. Evidence for a role of a TNF-alpha-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J. Biol. Chem. 1999, 274:13613-13618.
23. Romas E., Udagawa N., Zhou H., et al. The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J. Exp. Med. 1996, 183:2581-2591.